<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Integr Pharm Res Pract</journal-id><journal-id journal-id-type="iso-abbrev">Integr Pharm Res Pract</journal-id><journal-id journal-id-type="publisher-id">Integrated Pharmacy Research and Practice</journal-id><journal-title-group><journal-title>Integrated Pharmacy Research &#x00026; Practice</journal-title></journal-title-group><issn pub-type="epub">2230-5254</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29354534</article-id><article-id pub-id-type="pmc">5741033</article-id><article-id pub-id-type="doi">10.2147/IPRP.S92448</article-id><article-id pub-id-type="publisher-id">iprp-5-011</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Chronic care model in primary care: can it improve health-related quality of life?</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Aryani</surname><given-names>Faridah Md Yusof</given-names></name><xref ref-type="aff" rid="af1-iprp-5-011">1</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Shaun Wen Huey</given-names></name><xref ref-type="aff" rid="af2-iprp-5-011">2</xref><xref ref-type="corresp" rid="c1-iprp-5-011"/></contrib><contrib contrib-type="author"><name><surname>Chua</surname><given-names>Siew Siang</given-names></name><xref ref-type="aff" rid="af3-iprp-5-011">3</xref></contrib><contrib contrib-type="author"><name><surname>Kok</surname><given-names>Li Ching</given-names></name><xref ref-type="aff" rid="af4-iprp-5-011">4</xref></contrib><contrib contrib-type="author"><name><surname>Efendie</surname><given-names>Benny</given-names></name><xref ref-type="aff" rid="af2-iprp-5-011">2</xref></contrib><contrib contrib-type="author"><name><surname>Paraidathathu</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="af5-iprp-5-011">5</xref></contrib></contrib-group><aff id="af1-iprp-5-011">
<label>1</label>Pharmaceutical Services Division, Ministry of Health Malaysia, Petaling Jaya</aff><aff id="af2-iprp-5-011">
<label>2</label>School of Pharmacy, Monash University Malaysia, Bandar Sunway</aff><aff id="af3-iprp-5-011">
<label>3</label>Department of Pharmacy, Faculty of Medicine, University of Malaya</aff><aff id="af4-iprp-5-011">
<label>4</label>Clinical Research Centre, Kuala Lumpur Hospital, Kuala Lumpur</aff><aff id="af5-iprp-5-011">
<label>5</label>School of Pharmacy, Taylor&#x02019;s University, Subang Jaya, Selangor, Malaysia</aff><author-notes><corresp id="c1-iprp-5-011">Correspondence: Shaun Wen Huey Lee, School of Pharmacy, Monash University Malaysia, Jalan Lagoon Selatan, 46150 Bandar Sunway, Selangor, Malaysia, Tel +60 3 5514 5890, Fax +60 3 5514 6323, Email <email>shaun.lee@monash.edu</email></corresp></author-notes><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>19</day><month>1</month><year>2016</year></pub-date><volume>5</volume><fpage>11</fpage><lpage>17</lpage><permissions><copyright-statement>&#x000a9; 2016 Aryani et al. This work is published and licensed by Dove Medical Press Limited</copyright-statement><copyright-year>2016</copyright-year><license><license-p>The full terms of this license are available at <ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution &#x02013; Non Commercial (unported, v3.0) License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.</license-p></license></permissions><abstract><sec><title>Purpose</title><p>Chronic diseases such as hypertension, diabetes mellitus, and hyperlipidemia are public health concerns. However, little is known about how these affect patient-level health measures. The aim of the study was to examine the impact of a chronic care model (CCM) on the participant&#x02019;s health-related quality of life (QoL).</p></sec><sec><title>Patients and methods</title><p>Participants received either usual care or CCM by a team of health care professionals including pharmacists, nurses, dietitians, and general practitioners. The participants in the intervention group received medication counseling, adherence, and dietary advice from the health care team. The QoL was measured using the EQ-5D (EuroQoL-five dimension, health-related quality of life questionnaire) and comparison was made between usual care and intervention groups at the beginning and end of the study at 6 months.</p></sec><sec><title>Results</title><p>Mean (standard deviation) EQ-5D index scores improved significantly in the intervention group (0.92&#x000b1;0.10 vs 0.95&#x000b1;0.08; <italic>P</italic>&#x02264;0.01), but not in the usual care group (0.94&#x000b1;0.09 vs 0.95&#x000b1;0.09; <italic>P</italic>=0.084). Similarly, more participants in the intervention group reported improvements in their QoL compared with the usual care group, especially in the pain/discomfort and anxiety/depression dimensions.</p></sec><sec><title>Conclusion</title><p>The implementation of the CCM resulted in significant improvement in QoL. An interdisciplinary team CCM approach should be encouraged, to ultimately result in behavior changes and improve the QoL of the patients.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>diabetes mellitus</kwd><kwd>hypertension</kwd><kwd>hyperlipidemia</kwd><kwd>quality of life</kwd><kwd>EQ-5D</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Diabetes mellitus, cardiovascular, and chronic kidney diseases are the major causes of mortality, and the prevalence of these diseases is increasing worldwide.<xref rid="b1-iprp-5-011" ref-type="bibr">1</xref> Despite established national and international clinical guidelines as well as effective pharmacotherapy,<xref rid="b2-iprp-5-011" ref-type="bibr">2</xref>&#x02013;<xref rid="b4-iprp-5-011" ref-type="bibr">4</xref> the management of these major diseases remains suboptimal. This situation is a major concern for Malaysia, where these diseases have reached epidemic proportions.<xref rid="b5-iprp-5-011" ref-type="bibr">5</xref> The data from the recently concluded National Health and Morbidity survey showed that the prevalence of hypertension had increased from 32.2% in 2006 to 32.7% in 2011 for those aged 18 years and above. Similarly, the prevalence of diabetes has also increased by 31% in 5 years, from 11.6% in 2006 to 15.2% in 2011 and hyperlipidemia from 20.6% in 2006 to 35.1% in 2011 in those aged 18 years and above.<xref rid="b5-iprp-5-011" ref-type="bibr">5</xref>,<xref rid="b6-iprp-5-011" ref-type="bibr">6</xref></p><p>Therefore, creative solutions are required to address the increasing health care demand of noncommunicable disease in the country. There is growing evidence worldwide suggesting the integration of health care that provides patient-centered care, such as the chronic care model (CCM) is a feasible solution to this problem.<xref rid="b7-iprp-5-011" ref-type="bibr">7</xref>,<xref rid="b8-iprp-5-011" ref-type="bibr">8</xref> The CCM is an evidence-based framework that advocates evidence-based health care system changes especially in primary care setting needed to improve the patient outcomes.<xref rid="b9-iprp-5-011" ref-type="bibr">9</xref>,<xref rid="b10-iprp-5-011" ref-type="bibr">10</xref> In the current study, five of the six key components of CCM were used namely: patient empowerment and self-management support; delivery system design; decision support; clinical information systems, and finally community resources.</p><p>We recently conducted a study examining the use of this model in single as well as multiple chronic diseases. The primary prevention program, known as the Community Based Multiple Risk Factors Intervention Strategy (CORFIS) was a prospective, open label, multi-center, cluster-randomized study encompassing the services of general practitioners (GPs), pharmacists, nurses as well as dietitians, working together with 784 participants to improve their health outcomes by providing health education, medication counseling, treatment adherence as well as diet plan. Due to the popularity of CCM as a conceptual tool for quality improvement and health care reorganization, there is a need to determine if such interdisciplinary team approach produces better health status outcome. The objective of this study was to assess the impact of the CCM program on patient health-related quality of life (QoL).</p></sec><sec sec-type="methods|subjects"><title>Patients and methods</title><sec sec-type="methods"><title>Study design and setting</title><p>This study was part of a larger community-based, controlled study, which has been described earlier.<xref rid="b11-iprp-5-011" ref-type="bibr">11</xref>,<xref rid="b12-iprp-5-011" ref-type="bibr">12</xref> Briefly, GPs from the Klang valley were invited to participate in recruiting the patients for this study.<xref rid="b13-iprp-5-011" ref-type="bibr">13</xref> Participating GP clinics were subsequently allocated to either intervention or control in a 2:1 ratio. Any participants aged 18 years and above, diagnosed with either one or more of the following diseases: hypertension, diabetes mellitus, or hyperlipidemia, and treated with pharmacotherapy for one or more of these conditions were eligible for inclusion in the study. All the participants provided written informed consent. Ethical approval was obtained from the Medical Research Ethics Committee, Ministry of Health, Malaysia (NMRR-07-688-960). Trial registration: <ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link>, NCT00490672.</p></sec><sec sec-type="methods"><title>Study procedures</title><p>The participants allocated to the intervention cluster were required to attend a monthly check-up during the 6-month follow-up study period, with assessments by the pharmacist who reviewed the participants&#x02019; medications and provided counseling on adherence, medication knowledge as well as conducted medication reconciliation of existing prescription medications; dietitians who provided dietary advice including calorie calculations and the importance of regular exercise; and nurses who educated the participants on general health care issues such as the use of a glucose meter and foot care. Participants&#x02019; sociodemographic data, lifestyle, medical, and medication history were collected at baseline. In addition, the health-related QoL of each participant was assessed using the EQ-5D (EuroQoL-five dimension, health-related quality of life questionnaire) at baseline and at the end of the 6-month study period.</p></sec><sec><title>Outcome measures</title><p>The EQ-5D instrument is a standard instrument for measuring health outcome and has been validated for use in the Malaysian population.<xref rid="b14-iprp-5-011" ref-type="bibr">14</xref>,<xref rid="b15-iprp-5-011" ref-type="bibr">15</xref> This instrument provides a simple descriptive profile and a single index value for assessing health status. It comprises of five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) with three levels of measurement each (no problems, some problems, and severe problems). It has been used in several studies to assess the QoL of patients with diabetes,<xref rid="b16-iprp-5-011" ref-type="bibr">16</xref>&#x02013;<xref rid="b18-iprp-5-011" ref-type="bibr">18</xref> hypertension,<xref rid="b18-iprp-5-011" ref-type="bibr">18</xref>&#x02013;<xref rid="b20-iprp-5-011" ref-type="bibr">20</xref> and hyperlipidemia.<xref rid="b18-iprp-5-011" ref-type="bibr">18</xref> The raw values obtained from the dimension scales were subsequently converted into the Malaysian EQ-5D index tariff to obtain an overall health index score, with higher values representing better QoL. This ranges between 0 (represents death) and 1.0 (represents perfect health status).<xref rid="b21-iprp-5-011" ref-type="bibr">21</xref> The patients also completed the EQ-5D visual analog scale (EQ-VAS), a 20 cm long VAS where the patients marked their current health status ranging from &#x0201c;best imaginable health state&#x0201d; (score of 100) to &#x0201c;worst imaginable health state&#x0201d; (score of 0).</p><p>The primary endpoint was a 0.03 point increase in the EQ-5D index and a 3.0 point increase in the EQ-VAS from baseline to 6 months, based on consensus opinion and published recommendations available.<xref rid="b22-iprp-5-011" ref-type="bibr">22</xref> Secondary outcomes include changes in EQ-5D index and subscales in the various subgroups of participants as well as the EQ-VAS score.</p></sec><sec sec-type="methods"><title>Data analysis</title><p>All analyses were carried out with the PASW Statistics for Windows version 18 (SPSS Inc., Chicago, IL, USA). An intent-to-treat analysis was undertaken, whereby missing data were replaced using the last observation carry forward method. Continuous variables were summarized as means and standard deviations while frequencies and percentages were generated for categorical variables. Statistical comparison of endpoints was done using a paired <italic>t</italic>-test. We subsequently adjusted for age, occupational status, and education status to estimate the effects of intervention on QoL using a generalized estimating equation (GEE). All analyses were conducted separately for the patients with hypertension, diabetes, and hyperlipidemia. Any <italic>P</italic>-value less than 0.05 was considered as statistically significant.</p></sec></sec><sec sec-type="results"><title>Results</title><sec sec-type="intro|subjects"><title>Demographic characteristics of participants</title><p>A total of 784 participants who were diagnosed with hypertension, diabetes mellitus and/or hyperlipidemia, and treated with pharmacotherapy were enrolled into the study: 527 in the intervention arm and 257 in the usual care arm (<xref ref-type="fig" rid="f1-iprp-5-011">Figure 1</xref>). However, complete data were available for only 468 participants in the intervention group and 225 participants in the usual care group, giving a response rate of 88.4%. <xref ref-type="table" rid="t1-iprp-5-011">Table 1</xref> shows the demographic characteristics of the participants. Men constituted 59.3% (n=411) of the total respondents and almost half of the participants were of Malay ethnic origin (n=312, 45.0%). Most of the participants had some forms of formal education. Smoking of tobacco was reported by 15.3% (n=106) of the participants. As there were significant differences in the baseline characteristics, comparisons between both arms were not performed.</p></sec><sec><title>Quality of life</title><sec><title>QoL for intervention groups</title><p>Reported EQ-VAS QoL improved significantly by 6 points in the intervention group from 70.7 to 76.8 (<italic>P</italic>&#x0003c;0.001) and only by 1.7 points in the usual care group to 72.4 (<italic>P</italic>=0.314). Mean calculated EQ-5D index score also increased significantly by 0.03 points from 0.92 to 0.95 in the intervention group (<italic>P</italic>&#x02264;0.001). The patients in the usual care group reported an EQ-5D score of 0.94 which increased marginally to 0.95 at the end of the study (<xref ref-type="table" rid="t2-iprp-5-011">Table 2</xref>). In addition, the number of participants reporting a minimum meaningful improvement in the QoL was numerically higher in the intervention group compared with the usual care group (24.6% vs 8.0% reporting a 0.03 point improvement in the EQ-5D index score; <xref ref-type="table" rid="t3-iprp-5-011">Table 3</xref>). After adjusting for baseline differences, the intervention was associated with an improvement in EQ-VAS score but not EQ-5D scores (<xref ref-type="table" rid="t4-iprp-5-011">Table 4</xref>).</p></sec><sec><title>QoL for various disease states</title><p>The intervention was associated with an improvement in QoL and EQ-VAS score in all the three disease states studied (<xref ref-type="table" rid="t5-iprp-5-011">Table 5</xref>). A modest improvement in EQ-VAS score was observed in the usual care group but this did not reach statistical significance. During the study, QoL increased significantly in the intervention group irrespective of disease state, resulting in &#x0003e;80% of the patients reporting no problem for all the five dimensions studied. The biggest improvement was noted in the pain/discomfort dimension where there was a statistical improvement in all the three disease groups studied, followed by anxiety/depression dimension which was significantly improved in the patients with diabetes in the intervention group. No differences were noted in the usual care group at the end of the study (<xref ref-type="table" rid="t4-iprp-5-011">Table 4</xref>). The GEE analysis revealed that age and race were strongly associated with better EQ-VAS score and QoL, respectively, in the patients with hyperlipidemia (<italic>P</italic>&#x0003c;0.05). However, there were no associations between age, education, employment status, and race in the patients with hypertension and diabetes.</p></sec></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>Metabolic diseases have been shown to negatively impact a person&#x02019;s QoL.<xref rid="b23-iprp-5-011" ref-type="bibr">23</xref> In this multi-center study, the involvement of other health care professionals in addition to usual GP care was found to significantly improve the QoL of participants as well as their health status after 6-month participation. These improvements could be attributed to several factors namely: improved patient compliance, modification of diet and lifestyle, psychological support as well as patient empowerment. This combined strategy is simple, culturally acceptable and easily scaled up, and does not require any access to specialist services which may be scarce in a developing country. The data from this study concur and further support those from various other similar studies,<xref rid="b17-iprp-5-011" ref-type="bibr">17</xref>,<xref rid="b24-iprp-5-011" ref-type="bibr">24</xref> suggesting that these benefits can be realized in clinical practice, which is reflected by an improvement in QoL from a patient&#x02019;s perspective.</p><p>To our knowledge, this is the first community-based controlled trial of its kind in the South East Asian region, where the burden of cardiovascular and chronic kidney diseases is high.<xref rid="b25-iprp-5-011" ref-type="bibr">25</xref> The study involved a large patient number in a community-based setting, with close follow-up for 6 months. We used the EQ-5D questionnaire, which has been widely used in various studies and validated in the Malaysian population.<xref rid="b14-iprp-5-011" ref-type="bibr">14</xref>,<xref rid="b15-iprp-5-011" ref-type="bibr">15</xref>,<xref rid="b20-iprp-5-011" ref-type="bibr">20</xref>,<xref rid="b26-iprp-5-011" ref-type="bibr">26</xref> Thirdly, we initiated a study which focused on empowering the patient to manage their own conditions such as providing dietary counseling, training on insulin injection, and self-monitoring of blood glucose to achieve their individual metabolic targets. This is highly novel in Malaysia and was not available at the point of time the study was conducted.</p><p>This study has some potential limitations which need to be addressed. Firstly, it included various types of the patients with a wide range of drug regimens. It is possible that the improvement in the patient&#x02019;s condition or even adherence may have led to this improvement in the QoL. However, as the results of this study reflect actual medical condition, we believe the results will provide useful information and insights into the patient&#x02019;s concerns and hopes. Secondly, the study was relatively short and hence underpowered to determine its effects on cardiovascular outcomes such as mortality. Nevertheless, the data from other studies suggest that a sustained systolic blood pressure reduction of 5% would reduce the absolute risk of cardiovascular death by 20% over the next 2 decades. Similarly, the UK Prospective Diabetes Study study has shown that a 1% reduction in HbA<sub>1c</sub> will reduce microvascular and macrovascular complications over the next 10 years.<xref rid="b27-iprp-5-011" ref-type="bibr">27</xref> Lastly, the allocation of GP clinics to the usual care or intervention group could not be performed at random due to logistic reasons and also the willingness of GP clinics to participate in the study. To encourage participation, a 2:1 ratio of intervention to usual care randomization was adopted. This probably resulted in differences in the baseline characteristics between the two cohorts of participants, which may contribute to the differences in the results.</p></sec><sec><title>Conclusion</title><p>Implementation of the CCM into GP practice was significantly related to improved QoL of the participants, highlighting the importance of a multi-disciplinary team approach to provide collaborative care to the patients with chronic conditions. An adaptation of the CCM model may serve as a template for future health care system remodeling, to help improve access to quality and effective health care services especially in primary care.</p></sec></body><back><ack><title>Acknowledgments</title><p>We are grateful to the Director General of Health, Malaysia, for permission to publish this article, and to the Clinical Research Centre (CRC), Ministry of Health, Malaysia for supporting this study. Our greatest appreciation goes to the CORFIS team, especially to Dr Lim Teck Onn and Dr Zaki Morad Mohd Zaher, the principal investigators, and to Mr Wilson Low Hong Hoo, Mr Tang Guang Hui, Ms Dan Siew Peng, Ms Kimberly Wong, Ms Nor Fasihah Yahaya, and Ms M Vatsala Nair Manoha for coordinating the CORFIS trial. We also express our utmost gratitude to all the service pharmacists, dietitians, nurses, and GPs for their support, as well as to all the participants in this study for their cooperation.</p></ack><fn-group><fn><p><bold>Author contributions</bold></p><p>FMYA conceived, directed, and designed the CORFIS study. SWHL conducted statistical analyses. SSC designed the CORFIS study and assisted in statistical analyses. BE and TP participated in the study design. LCK coordinated the CORFIS study. All authors contributed toward data analysis, drafting and critically revising the paper, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.</p></fn><fn fn-type="COI-statement"><p><bold>Disclosure</bold></p><p>The authors report no conflicts of interest in this work.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-iprp-5-011"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lozano</surname><given-names>R</given-names></name><name><surname>Naghavi</surname><given-names>M</given-names></name><name><surname>Foreman</surname><given-names>K</given-names></name><etal/></person-group><article-title>Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010</article-title><source>Lancet</source><year>2012</year><volume>380</volume><issue>9859</issue><fpage>2095</fpage><lpage>2128</lpage><pub-id pub-id-type="pmid">23245604</pub-id></element-citation></ref><ref id="b2-iprp-5-011"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chobanian</surname><given-names>AV</given-names></name><name><surname>Bakris</surname><given-names>GL</given-names></name><name><surname>Black</surname><given-names>HR</given-names></name><etal/></person-group><article-title>Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure</article-title><source>Hypertension</source><year>2003</year><volume>42</volume><issue>6</issue><fpage>1206</fpage><lpage>1252</lpage><pub-id pub-id-type="pmid">14656957</pub-id></element-citation></ref><ref id="b3-iprp-5-011"><label>3</label><element-citation publication-type="journal"><article-title>Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final report</article-title><source>Circulation</source><year>2002</year><volume>106</volume><issue>25</issue><fpage>3143</fpage><pub-id pub-id-type="pmid">12485966</pub-id></element-citation></ref><ref id="b4-iprp-5-011"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Members</surname><given-names>ATF</given-names></name><name><surname>Mancia</surname><given-names>G</given-names></name><name><surname>Fagard</surname><given-names>R</given-names></name><etal/></person-group><article-title>2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)</article-title><source>Eur Heart J</source><year>2013</year><volume>31</volume><issue>7</issue><fpage>1281</fpage><lpage>1357</lpage></element-citation></ref><ref id="b5-iprp-5-011"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amal</surname><given-names>NM</given-names></name><name><surname>Paramesarvathy</surname><given-names>R</given-names></name><name><surname>Tee</surname><given-names>GH</given-names></name><name><surname>Gurpreet</surname><given-names>K</given-names></name><name><surname>Karuthan</surname><given-names>C</given-names></name></person-group><article-title>Prevalence of chronic illness and health seeking behaviour in Malaysian population: results from the Third National Health Morbidity Survey (NHMS III) 2006</article-title><source>Med J Malaysia</source><year>2011</year><volume>66</volume><issue>1</issue><fpage>36</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">23765141</pub-id></element-citation></ref><ref id="b6-iprp-5-011"><label>6</label><element-citation publication-type="journal"><comment>No authors listed</comment><article-title>NCD Pervention and Control Annual Report 2011</article-title><source>Section N-CD Putrajaya: Ministry of Health Malaysia</source><year>2011</year><fpage>735</fpage></element-citation></ref><ref id="b7-iprp-5-011"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davy</surname><given-names>C</given-names></name><name><surname>Bleasel</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Tchan</surname><given-names>M</given-names></name><name><surname>Ponniah</surname><given-names>S</given-names></name><name><surname>Brown</surname><given-names>A</given-names></name></person-group><article-title>Effectiveness of chronic care models: opportunities for improving healthcare practice and health outcomes: a systematic review</article-title><source>BMC Health Serv Res</source><year>2015</year><volume>15</volume><issue>1</issue><fpage>194</fpage><pub-id pub-id-type="pmid">25958128</pub-id></element-citation></ref><ref id="b8-iprp-5-011"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stellefson</surname><given-names>M</given-names></name><name><surname>Dipnarine</surname><given-names>K</given-names></name><name><surname>Stopka</surname><given-names>C</given-names></name></person-group><article-title>The chronic care model and diabetes management in US primary care settings: a systematic review</article-title><source>Prevent Chron Dis</source><year>2013</year><volume>10</volume><fpage>E26</fpage></element-citation></ref><ref id="b9-iprp-5-011"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bodenheimer</surname><given-names>T</given-names></name><name><surname>Wagner</surname><given-names>EH</given-names></name><name><surname>Grumbach</surname><given-names>K</given-names></name></person-group><article-title>Improving primary care for patients with chronic illness: the chronic care model, part 2</article-title><source>JAMA</source><year>2002</year><volume>288</volume><issue>15</issue><fpage>1909</fpage><lpage>1914</lpage><pub-id pub-id-type="pmid">12377092</pub-id></element-citation></ref><ref id="b10-iprp-5-011"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bodenheimer</surname><given-names>T</given-names></name></person-group><article-title>Interventions to improve chronic illness care: evaluating their effectiveness</article-title><source>Dis Manag</source><year>2003</year><volume>6</volume><issue>2</issue><fpage>63</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">14577900</pub-id></element-citation></ref><ref id="b11-iprp-5-011"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Low</surname><given-names>W</given-names></name><name><surname>Seet</surname><given-names>W</given-names></name><name><surname>Ramli</surname><given-names>AS</given-names></name><etal/></person-group><article-title>Community-based cardiovascular Risk Factors Intervention Strategies (CORFIS) in managing hypertension: A pragmatic non-randomised control</article-title><source>Med J Malaysia</source><year>2013</year><volume>68</volume><issue>2</issue><fpage>129</fpage><lpage>135</lpage><pub-id pub-id-type="pmid">23629558</pub-id></element-citation></ref><ref id="b12-iprp-5-011"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chua</surname><given-names>S</given-names></name><name><surname>Kok</surname><given-names>L</given-names></name><name><surname>Yusof</surname><given-names>FA</given-names></name><etal/></person-group><article-title>Pharmaceutical care issues identified by pharmacists in patients with diabetes, hypertension or hyperlipidaemia in primary care settings</article-title><source>BMC Health Serv Res</source><year>2012</year><volume>12</volume><issue>1</issue><fpage>388</fpage><pub-id pub-id-type="pmid">23145922</pub-id></element-citation></ref><ref id="b13-iprp-5-011"><label>13</label><element-citation publication-type="book"><comment>No authors or editors listed</comment><article-title>Demographic Indicators Malaysia</article-title><source>Malaysia DoS Putrajaya: Department of Statistics</source><publisher-loc>Malaysia</publisher-loc><year>2012</year></element-citation></ref><ref id="b14-iprp-5-011"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shafie</surname><given-names>A</given-names></name><name><surname>Hassali</surname><given-names>M</given-names></name><name><surname>Liau</surname><given-names>S</given-names></name></person-group><article-title>A cross-sectional validation study of EQ-5D among the Malaysian adult population</article-title><source>Q Life Res</source><year>2011</year><volume>20</volume><issue>4</issue><fpage>593</fpage><lpage>600</lpage></element-citation></ref><ref id="b15-iprp-5-011"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varatharajan</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>W-S</given-names></name></person-group><article-title>Reliability and validity of EQ-5D in Malaysian population</article-title><source>Appl Res Q Life</source><year>2012</year><volume>7</volume><issue>2</issue><fpage>209</fpage><lpage>221</lpage></element-citation></ref><ref id="b16-iprp-5-011"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morgan</surname><given-names>CL</given-names></name><name><surname>McEwan</surname><given-names>P</given-names></name><name><surname>Morrissey</surname><given-names>M</given-names></name><name><surname>Peters</surname><given-names>JR</given-names></name><name><surname>Poole</surname><given-names>C</given-names></name><name><surname>Currie</surname><given-names>CJ</given-names></name></person-group><article-title>Characterization and comparison of health-related utility in people with diabetes with various single and multiple vascular complications</article-title><source>Diabetic Medicine</source><year>2006</year><volume>23</volume><issue>10</issue><fpage>1100</fpage><lpage>1105</lpage><pub-id pub-id-type="pmid">16978374</pub-id></element-citation></ref><ref id="b17-iprp-5-011"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Currie</surname><given-names>C</given-names></name><name><surname>Poole</surname><given-names>C</given-names></name><name><surname>Woehl</surname><given-names>A</given-names></name><etal/></person-group><article-title>The health-related utility and health-related quality of life of hospital-treated subjects with type 1 or type 2 diabetes with particular reference to differing severity of peripheral neuropathy</article-title><source>Diabetologia</source><year>2006</year><volume>49</volume><issue>10</issue><fpage>2272</fpage><lpage>2280</lpage><pub-id pub-id-type="pmid">16944094</pub-id></element-citation></ref><ref id="b18-iprp-5-011"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sullivan</surname><given-names>PW</given-names></name><name><surname>Ghushchyan</surname><given-names>V</given-names></name><name><surname>Wyatt</surname><given-names>HR</given-names></name><name><surname>Wu</surname><given-names>EQ</given-names></name><name><surname>Hill</surname><given-names>JO</given-names></name></person-group><article-title>Impact of cardiometabolic risk factor clusters on health-related quality of life in the US [ast]</article-title><source>Obesity</source><year>2007</year><volume>15</volume><issue>2</issue><fpage>511</fpage><lpage>511</lpage><pub-id pub-id-type="pmid">17299125</pub-id></element-citation></ref><ref id="b19-iprp-5-011"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bharmal</surname><given-names>M</given-names></name><name><surname>Thomas</surname><given-names>J</given-names></name></person-group><article-title>Comparing the EQ-5D and the SF-6D descriptive systems to assess their ceiling effects in the US general population</article-title><source>Value Health</source><year>2006</year><volume>9</volume><issue>4</issue><fpage>262</fpage><lpage>271</lpage><pub-id pub-id-type="pmid">16903996</pub-id></element-citation></ref><ref id="b20-iprp-5-011"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ko</surname><given-names>Y</given-names></name><name><surname>Coons</surname><given-names>SJ</given-names></name></person-group><article-title>Self-reported chronic conditions and EQ-5D index scores in the US adult population</article-title><source>Curr Med Res Opin</source><year>2006</year><volume>22</volume><issue>10</issue><fpage>2065</fpage><lpage>2071</lpage><pub-id pub-id-type="pmid">17031907</pub-id></element-citation></ref><ref id="b21-iprp-5-011"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Md Yusof</surname><given-names>FA</given-names></name><name><surname>Goh</surname><given-names>A</given-names></name><name><surname>Azmi</surname><given-names>S</given-names></name></person-group><article-title>Estimating an EQ-5D value set for Malaysia using time trade-off and visual analogue scale methods</article-title><source>Value Health</source><year>2012</year><volume>15</volume><issue>1</issue><fpage>S85</fpage><lpage>S90</lpage><pub-id pub-id-type="pmid">22265073</pub-id></element-citation></ref><ref id="b22-iprp-5-011"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>N</given-names></name><name><surname>Johnson</surname><given-names>JA</given-names></name><name><surname>Coons</surname><given-names>SJ</given-names></name></person-group><article-title>Using instrument-defined health state transitions to estimate minimally important differences for four preference-based health-related quality of life instruments</article-title><source>Med Care</source><year>2010</year><volume>48</volume><issue>4</issue><fpage>365</fpage><lpage>371</lpage><pub-id pub-id-type="pmid">20355266</pub-id></element-citation></ref><ref id="b23-iprp-5-011"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ford</surname><given-names>ES</given-names></name><name><surname>Li</surname><given-names>C</given-names></name></person-group><article-title>Metabolic syndrome and health-related quality of life among US Adults</article-title><source>Ann Epidemiol</source><year>2008</year><volume>18</volume><issue>3</issue><fpage>165</fpage><lpage>171</lpage><pub-id pub-id-type="pmid">18280918</pub-id></element-citation></ref><ref id="b24-iprp-5-011"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>EH</given-names></name><name><surname>Austin</surname><given-names>BT</given-names></name><name><surname>Davis</surname><given-names>C</given-names></name><name><surname>Hindmarsh</surname><given-names>M</given-names></name><name><surname>Schaefer</surname><given-names>J</given-names></name><name><surname>Bonomi</surname><given-names>A</given-names></name></person-group><article-title>Improving chronic illness care: translating evidence into action</article-title><source>Health Affairs</source><year>2001</year><volume>20</volume><issue>6</issue><fpage>64</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">11816692</pub-id></element-citation></ref><ref id="b25-iprp-5-011"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dhillon</surname><given-names>PK</given-names></name><name><surname>Jeemon</surname><given-names>P</given-names></name><name><surname>Arora</surname><given-names>NK</given-names></name><etal/></person-group><article-title>Status of epidemiology in the WHO South-East Asia region: burden of disease, determinants of health and epidemiological research, workforce and training capacity</article-title><source>Int J Epidemiol</source><year>2012</year><volume>41</volume><issue>3</issue><fpage>847</fpage><lpage>860</lpage><pub-id pub-id-type="pmid">22617689</pub-id></element-citation></ref><ref id="b26-iprp-5-011"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>S</given-names></name><name><surname>Zilov</surname><given-names>A</given-names></name><name><surname>Malek</surname><given-names>R</given-names></name><name><surname>Soewondo</surname><given-names>P</given-names></name><name><surname>Bech</surname><given-names>O</given-names></name><name><surname>Litwak</surname><given-names>L</given-names></name></person-group><article-title>Improvements in quality of life associated with insulin analogue therapies in people with type 2 diabetes: Results from the A1chieve observational study</article-title><source>Diabet Res Clin Pract</source><year>2011</year><volume>94</volume><issue>3</issue><fpage>364</fpage><lpage>370</lpage></element-citation></ref><ref id="b27-iprp-5-011"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chalmers</surname><given-names>J</given-names></name><name><surname>Cooper</surname><given-names>ME</given-names></name></person-group><article-title>UKPDS and the legacy effect</article-title><source>New Eng J Med</source><year>2008</year><volume>359</volume><issue>15</issue><fpage>1618</fpage><lpage>1620</lpage><pub-id pub-id-type="pmid">18843126</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-iprp-5-011" position="float"><label>Figure 1</label><caption><p>Flowchart of participants in the study.</p><p><bold>Note:</bold> *Participants who successfully completed 6 months follow-up were included in the analysis.</p><p><bold>Abbreviation:</bold> GP, general practitioner.</p></caption><graphic xlink:href="iprp-5-011Fig1"/></fig><table-wrap id="t1-iprp-5-011" position="float"><label>Table 1</label><caption><p>Baseline demographics and clinical characteristics of participants in the study</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Variable</th><th valign="top" align="left" rowspan="1" colspan="1">Intervention group (n=468)</th><th valign="top" align="left" rowspan="1" colspan="1">Usual care group (n=225)</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Mean age (SD), years</td><td valign="top" align="left" rowspan="1" colspan="1">47.4 (9.4)</td><td valign="top" align="left" rowspan="1" colspan="1">50.1 (10.2)</td><td valign="top" align="left" rowspan="1" colspan="1">0.001<xref ref-type="table-fn" rid="tfn2-iprp-5-011">**</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Sex, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">0.163<xref ref-type="table-fn" rid="tfn1-iprp-5-011">*</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Male</td><td valign="top" align="left" rowspan="1" colspan="1">286 (61.1)</td><td valign="top" align="left" rowspan="1" colspan="1">125 (55.6)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Female</td><td valign="top" align="left" rowspan="1" colspan="1">182 (38.9)</td><td valign="top" align="left" rowspan="1" colspan="1">100 (44.4)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Race, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;0.001<xref ref-type="table-fn" rid="tfn1-iprp-5-011">*</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Malay</td><td valign="top" align="left" rowspan="1" colspan="1">208 (44.4)</td><td valign="top" align="left" rowspan="1" colspan="1">104 (46.2)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Chinese</td><td valign="top" align="left" rowspan="1" colspan="1">119 (25.4)</td><td valign="top" align="left" rowspan="1" colspan="1">82 (36.4)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Indian</td><td valign="top" align="left" rowspan="1" colspan="1">125 (26.7)</td><td valign="top" align="left" rowspan="1" colspan="1">38 (16.9)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Others</td><td valign="top" align="left" rowspan="1" colspan="1">16 (3.5)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (0.5)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Employment status, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;0.001<xref ref-type="table-fn" rid="tfn1-iprp-5-011">*</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Employed</td><td valign="top" align="left" rowspan="1" colspan="1">368 (78.6)</td><td valign="top" align="left" rowspan="1" colspan="1">162 (72.0)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Jobless</td><td valign="top" align="left" rowspan="1" colspan="1">11 (2.4)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (0.4)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Housewife</td><td valign="top" align="left" rowspan="1" colspan="1">46 (9.8)</td><td valign="top" align="left" rowspan="1" colspan="1">49 (21.8)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Retired</td><td valign="top" align="left" rowspan="1" colspan="1">43 (9.2)</td><td valign="top" align="left" rowspan="1" colspan="1">13 (5.8)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Education, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;0.001<xref ref-type="table-fn" rid="tfn1-iprp-5-011">*</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Primary</td><td valign="top" align="left" rowspan="1" colspan="1">25 (5.3)</td><td valign="top" align="left" rowspan="1" colspan="1">42 (18.7)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Secondary</td><td valign="top" align="left" rowspan="1" colspan="1">208 (44.4)</td><td valign="top" align="left" rowspan="1" colspan="1">116 (51.6)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Graduate and above</td><td valign="top" align="left" rowspan="1" colspan="1">176 (37.6)</td><td valign="top" align="left" rowspan="1" colspan="1">52 (23.1)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Illiterate</td><td valign="top" align="left" rowspan="1" colspan="1">59 (12.6)</td><td valign="top" align="left" rowspan="1" colspan="1">15 (6.7)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Disease status,<xref ref-type="table-fn" rid="tfn3-iprp-5-011">***</xref> n (%)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Hypertension</td><td valign="top" align="left" rowspan="1" colspan="1">306 (65.4)</td><td valign="top" align="left" rowspan="1" colspan="1">173 (76.9)</td><td valign="top" align="left" rowspan="1" colspan="1">0.002<xref ref-type="table-fn" rid="tfn1-iprp-5-011">*</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Hyperlipidemia</td><td valign="top" align="left" rowspan="1" colspan="1">268 (57.3)</td><td valign="top" align="left" rowspan="1" colspan="1">104 (46.2)</td><td valign="top" align="left" rowspan="1" colspan="1">0.006<xref ref-type="table-fn" rid="tfn1-iprp-5-011">*</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Diabetes</td><td valign="top" align="left" rowspan="1" colspan="1">292 (62.4)</td><td valign="top" align="left" rowspan="1" colspan="1">130 (57.8)</td><td valign="top" align="left" rowspan="1" colspan="1">0.244<xref ref-type="table-fn" rid="tfn1-iprp-5-011">*</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Tobacco use, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Past</td><td valign="top" align="left" rowspan="1" colspan="1">44 (9.4)</td><td valign="top" align="left" rowspan="1" colspan="1">13 (5.8)</td><td valign="top" align="left" rowspan="1" colspan="1">0.08<xref ref-type="table-fn" rid="tfn1-iprp-5-011">*</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Current</td><td valign="top" align="left" rowspan="1" colspan="1">78 (16.7)</td><td valign="top" align="left" rowspan="1" colspan="1">28 (12.4)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Never</td><td valign="top" align="left" rowspan="1" colspan="1">346 (73.9)</td><td valign="top" align="left" rowspan="1" colspan="1">184 (81.8)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn><p><bold>Notes:</bold></p></fn><fn id="tfn1-iprp-5-011"><label>*</label><p><italic>P</italic>-values based upon &#x003c7;<sup>2</sup> test;</p></fn><fn id="tfn2-iprp-5-011"><label>**</label><p><italic>P</italic>-values based upon <italic>t</italic>-test;</p></fn><fn id="tfn3-iprp-5-011"><label>***</label><p>percentage exceeds 100% as some patients had &#x0003e;1 disease state.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-iprp-5-011" position="float"><label>Table 2</label><caption><p>Distribution of participants reporting moderate or severe problems in different dimensions and the EQ-5D index scores</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"/><th valign="top" align="left" rowspan="1" colspan="1">Baseline</th><th valign="top" align="left" rowspan="1" colspan="1">End of study</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Intervention group (n=468)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Mobility, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1">32 (6.8)</td><td valign="top" align="left" rowspan="1" colspan="1">25 (5.3)</td><td valign="top" align="left" rowspan="1" colspan="1">0.412<xref ref-type="table-fn" rid="tfn5-iprp-5-011">*</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Self-care, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1">3 (0.6)</td><td valign="top" align="left" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="left" rowspan="1" colspan="1">0.249<xref ref-type="table-fn" rid="tfn5-iprp-5-011">*</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Usual activity, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1">21 (4.5)</td><td valign="top" align="left" rowspan="1" colspan="1">17 (3.6)</td><td valign="top" align="left" rowspan="1" colspan="1">0.514<xref ref-type="table-fn" rid="tfn5-iprp-5-011">*</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Pain/discomfort, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1">147 (31.4)</td><td valign="top" align="left" rowspan="1" colspan="1">81 (17.3)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;0.001<xref ref-type="table-fn" rid="tfn5-iprp-5-011">*</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Anxiety/depression, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1">112 (23.9)</td><td valign="top" align="left" rowspan="1" colspan="1">70 (15.0)</td><td valign="top" align="left" rowspan="1" colspan="1">0.001<xref ref-type="table-fn" rid="tfn5-iprp-5-011">*</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;EQ-5D index score, mean (SD)</td><td valign="top" align="left" rowspan="1" colspan="1">0.92 (0.10)</td><td valign="top" align="left" rowspan="1" colspan="1">0.95 (0.08)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;0.001<xref ref-type="table-fn" rid="tfn6-iprp-5-011">**</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;EQ VAS, mean (SD)</td><td valign="top" align="left" rowspan="1" colspan="1">70.74 (16.53)</td><td valign="top" align="left" rowspan="1" colspan="1">76.81 (15.28)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;0.001<xref ref-type="table-fn" rid="tfn6-iprp-5-011">**</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Usual care group (n=225)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Mobility, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1">10 (4.4)</td><td valign="top" align="left" rowspan="1" colspan="1">8 (3.6)</td><td valign="top" align="left" rowspan="1" colspan="1">0.641<xref ref-type="table-fn" rid="tfn5-iprp-5-011">*</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Self-care, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="left" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Usual activity, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1">5 (2.2)</td><td valign="top" align="left" rowspan="1" colspan="1">4 (1.8)</td><td valign="top" align="left" rowspan="1" colspan="1">0.752<xref ref-type="table-fn" rid="tfn5-iprp-5-011">*</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Pain/discomfort, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1">43 (19.1)</td><td valign="top" align="left" rowspan="1" colspan="1">41 (18.2)</td><td valign="top" align="left" rowspan="1" colspan="1">0.810<xref ref-type="table-fn" rid="tfn5-iprp-5-011">*</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Anxiety/depression, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1">46 (20.4)</td><td valign="top" align="left" rowspan="1" colspan="1">40 (17.8)</td><td valign="top" align="left" rowspan="1" colspan="1">0.548<xref ref-type="table-fn" rid="tfn5-iprp-5-011">*</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;EQ-5D index score, mean (SD)<xref ref-type="table-fn" rid="tfn6-iprp-5-011">**</xref></td><td valign="top" align="left" rowspan="1" colspan="1">0.94 (0.09)</td><td valign="top" align="left" rowspan="1" colspan="1">0.95 (0.09)</td><td valign="top" align="left" rowspan="1" colspan="1">0.084<xref ref-type="table-fn" rid="tfn5-iprp-5-011">*</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;EQ VAS, mean (SD)</td><td valign="top" align="left" rowspan="1" colspan="1">70.72 (25.42)</td><td valign="top" align="left" rowspan="1" colspan="1">72.35 (24.81)</td><td valign="top" align="left" rowspan="1" colspan="1">0.314<xref ref-type="table-fn" rid="tfn6-iprp-5-011">**</xref></td></tr></tbody></table><table-wrap-foot><fn><p><bold>Notes:</bold></p></fn><fn id="tfn4-iprp-5-011"><p>Data are utility value 0&#x02013;1 (mean [SD]), VAS scores 0&#x02013;100 (mean [SD]), and number and percentage of patients reporting problems within the five dimensions.</p></fn><fn id="tfn5-iprp-5-011"><label>*</label><p><italic>P</italic>-value based on &#x003c7;<sup>2</sup> test;</p></fn><fn id="tfn6-iprp-5-011"><label>**</label><p><italic>P</italic>-value based on paired <italic>t</italic>-test.</p></fn><fn id="tfn7-iprp-5-011"><p><bold>Abbreviations:</bold> EQ-5D, EuroQoL-five dimension, health-related quality of life questionnaire; EQ-VAS, EQ-5D visual analog scale.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t3-iprp-5-011" position="float"><label>Table 3</label><caption><p>Patients with a minimum clinically significant change in outcome from baseline to 6 months</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"/><th valign="top" align="left" rowspan="1" colspan="1">Intervention group</th><th valign="top" align="left" rowspan="1" colspan="1">Usual care group</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Whole cohort</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">EQ-5D index score</td><td valign="top" align="left" rowspan="1" colspan="1">n<sup>&#x02020;</sup>=468</td><td valign="top" align="left" rowspan="1" colspan="1">n<sup>&#x02020;</sup>=225</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Improving by &#x0003e; MIC, n<xref ref-type="table-fn" rid="tfn9-iprp-5-011">*</xref> (%)</td><td valign="top" align="left" rowspan="1" colspan="1">115 (24.6)</td><td valign="top" align="left" rowspan="1" colspan="1">18 (8.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Worsening by &#x0003e; MIC, n<xref ref-type="table-fn" rid="tfn9-iprp-5-011">*</xref> (%)</td><td valign="top" align="left" rowspan="1" colspan="1">33 (7.1)</td><td valign="top" align="left" rowspan="1" colspan="1">9 (4.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">EQ-VAS score</td><td valign="top" align="left" rowspan="1" colspan="1">n<sup>&#x02020;</sup>=460</td><td valign="top" align="left" rowspan="1" colspan="1">n<sup>&#x02020;</sup>=223</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Improving by &#x0003e; MIC, n<xref ref-type="table-fn" rid="tfn9-iprp-5-011">*</xref> (%)</td><td valign="top" align="left" rowspan="1" colspan="1">208 (45.2)</td><td valign="top" align="left" rowspan="1" colspan="1">46 (20.6)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Worsening by &#x0003e; MIC, n<xref ref-type="table-fn" rid="tfn9-iprp-5-011">*</xref> (%)</td><td valign="top" align="left" rowspan="1" colspan="1">67 (14.6)</td><td valign="top" align="left" rowspan="1" colspan="1">27 (12.1)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Hypertension</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">EQ-5D index score</td><td valign="top" align="left" rowspan="1" colspan="1">n<sup>&#x02020;</sup>=306</td><td valign="top" align="left" rowspan="1" colspan="1">n<sup>&#x02020;</sup>=173</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Improving by &#x0003e; MIC, n<xref ref-type="table-fn" rid="tfn9-iprp-5-011">*</xref> (%)</td><td valign="top" align="left" rowspan="1" colspan="1">76 (24.8)</td><td valign="top" align="left" rowspan="1" colspan="1">15 (8.7)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Worsening by &#x0003e; MIC, n<xref ref-type="table-fn" rid="tfn9-iprp-5-011">*</xref> (%)</td><td valign="top" align="left" rowspan="1" colspan="1">22 (7.2)</td><td valign="top" align="left" rowspan="1" colspan="1">7 (4.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">EQ-VAS score</td><td valign="top" align="left" rowspan="1" colspan="1">n<sup>&#x02020;</sup>=302</td><td valign="top" align="left" rowspan="1" colspan="1">n<sup>&#x02020;</sup>=172</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Improving by &#x0003e; MIC, n<xref ref-type="table-fn" rid="tfn9-iprp-5-011">*</xref> (%)</td><td valign="top" align="left" rowspan="1" colspan="1">141 (46.7)</td><td valign="top" align="left" rowspan="1" colspan="1">38 (22.1)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Worsening by &#x0003e; MIC, n<xref ref-type="table-fn" rid="tfn9-iprp-5-011">*</xref> (%)</td><td valign="top" align="left" rowspan="1" colspan="1">43 (14.2)</td><td valign="top" align="left" rowspan="1" colspan="1">19 (11.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Diabetes mellitus</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">EQ-5D index score</td><td valign="top" align="left" rowspan="1" colspan="1">n<sup>&#x02020;</sup>=306</td><td valign="top" align="left" rowspan="1" colspan="1">n<sup>&#x02020;</sup>=173</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Improving by &#x0003e; MIC, n<xref ref-type="table-fn" rid="tfn9-iprp-5-011">*</xref> (%)</td><td valign="top" align="left" rowspan="1" colspan="1">67 (25.0)</td><td valign="top" align="left" rowspan="1" colspan="1">6 (5.8)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Worsening by &#x0003e; MIC, n<xref ref-type="table-fn" rid="tfn9-iprp-5-011">*</xref> (%)</td><td valign="top" align="left" rowspan="1" colspan="1">20 (7.5)</td><td valign="top" align="left" rowspan="1" colspan="1">4 (3.8)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">EQ-VAS score</td><td valign="top" align="left" rowspan="1" colspan="1">n<sup>&#x02020;</sup>=262</td><td valign="top" align="left" rowspan="1" colspan="1">n<sup>&#x02020;</sup>=104</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Improving by &#x0003e; MIC, n<xref ref-type="table-fn" rid="tfn9-iprp-5-011">*</xref> (%)</td><td valign="top" align="left" rowspan="1" colspan="1">125 (47.7)</td><td valign="top" align="left" rowspan="1" colspan="1">24 (23.1)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Worsening by &#x0003e; MIC, n<xref ref-type="table-fn" rid="tfn9-iprp-5-011">*</xref> (%)</td><td valign="top" align="left" rowspan="1" colspan="1">36 (13.7)</td><td valign="top" align="left" rowspan="1" colspan="1">11 (10.6)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Hyperlipidemia</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">EQ-5D index score</td><td valign="top" align="left" rowspan="1" colspan="1">n<sup>&#x02020;</sup>=233</td><td valign="top" align="left" rowspan="1" colspan="1">n<sup>&#x02020;</sup>=106</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Improving by &#x0003e; MIC, n<xref ref-type="table-fn" rid="tfn9-iprp-5-011">*</xref> (%)</td><td valign="top" align="left" rowspan="1" colspan="1">55 (23.6)</td><td valign="top" align="left" rowspan="1" colspan="1">7 (6.6)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Worsening by &#x0003e; MIC, n<xref ref-type="table-fn" rid="tfn9-iprp-5-011">*</xref> (%)</td><td valign="top" align="left" rowspan="1" colspan="1">17 (7.3)</td><td valign="top" align="left" rowspan="1" colspan="1">6 (5.7)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">EQ-VAS score</td><td valign="top" align="left" rowspan="1" colspan="1">n<sup>&#x02020;</sup>=230</td><td valign="top" align="left" rowspan="1" colspan="1">n<sup>&#x02020;</sup>=104</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Improving by &#x0003e; MIC, n<xref ref-type="table-fn" rid="tfn9-iprp-5-011">*</xref> (%)</td><td valign="top" align="left" rowspan="1" colspan="1">105 (45.7)</td><td valign="top" align="left" rowspan="1" colspan="1">20 (19.2)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Worsening by &#x0003e; MIC, n<xref ref-type="table-fn" rid="tfn9-iprp-5-011">*</xref> (%)</td><td valign="top" align="left" rowspan="1" colspan="1">33 (14.3)</td><td valign="top" align="left" rowspan="1" colspan="1">17 (16.3)</td></tr></tbody></table><table-wrap-foot><fn><p><bold>Notes:</bold></p></fn><fn id="tfn8-iprp-5-011"><p>MIC, minimally important change defined as 0.03 points in the EQ-5D index score and 3 points in the EQ-VAS score.</p></fn><fn id="tfn9-iprp-5-011"><label>*</label><p>These numbers represent the number of patients who attended final visit 6-month postintervention, and percentages are based on these numbers. The number of patients with data for each endpoint (n<sup>&#x02020;</sup>) is presented before each endpoint.</p></fn><fn id="tfn10-iprp-5-011"><p><bold>Abbreviations:</bold> EQ-5D, EuroQoL-five dimension, health-related quality of life questionnaire; EQ-VAS, EQ-5D visual analog scale.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t4-iprp-5-011" position="float"><label>Table 4</label><caption><p>Results of the GEE regression analyses</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" valign="top" align="left" colspan="1">Parameter</th><th colspan="2" valign="top" align="left" rowspan="1">EQ-5D index score
<hr/></th><th colspan="2" valign="top" align="left" rowspan="1">EQ-VAS score
<hr/></th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">Estimate<break/>(SE)</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic>-value</th><th valign="top" align="left" rowspan="1" colspan="1">Estimate<break/>(SE)</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Intercept</td><td valign="top" align="left" rowspan="1" colspan="1">0.96 (0.04)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;0.01</td><td valign="top" align="left" rowspan="1" colspan="1">65.74 (7.0)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Allocation</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;CORFIS</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.01 (0.01)</td><td valign="top" align="left" rowspan="1" colspan="1">0.11</td><td valign="top" align="left" rowspan="1" colspan="1">1.44 (1.7)</td><td valign="top" align="left" rowspan="1" colspan="1">0.42</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Usual care (reference)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Education status</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Primary</td><td valign="top" align="left" rowspan="1" colspan="1">0.01 (0.02)</td><td valign="top" align="left" rowspan="1" colspan="1">0.64</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;7.46 (4.1)</td><td valign="top" align="left" rowspan="1" colspan="1">0.07</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Secondary</td><td valign="top" align="left" rowspan="1" colspan="1">0.01 (0.01)</td><td valign="top" align="left" rowspan="1" colspan="1">0.48</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.09 (2.4)</td><td valign="top" align="left" rowspan="1" colspan="1">0.97</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Tertiary</td><td valign="top" align="left" rowspan="1" colspan="1">0.02 (0.01)</td><td valign="top" align="left" rowspan="1" colspan="1">0.21</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.19 (2.6)</td><td valign="top" align="left" rowspan="1" colspan="1">0.64</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Illiterate (reference)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Race</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Malay</td><td valign="top" align="left" rowspan="1" colspan="1">0.03 (0.02)</td><td valign="top" align="left" rowspan="1" colspan="1">0.22</td><td valign="top" align="left" rowspan="1" colspan="1">4.41 (4.0)</td><td valign="top" align="left" rowspan="1" colspan="1">0.27</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Chinese</td><td valign="top" align="left" rowspan="1" colspan="1">0.02 (0.02)</td><td valign="top" align="left" rowspan="1" colspan="1">0.50</td><td valign="top" align="left" rowspan="1" colspan="1">3.76 (4.1)</td><td valign="top" align="left" rowspan="1" colspan="1">0.36</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Indian</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.01 (0.02)</td><td valign="top" align="left" rowspan="1" colspan="1">0.82</td><td valign="top" align="left" rowspan="1" colspan="1">4.79 (4.2)</td><td valign="top" align="left" rowspan="1" colspan="1">0.25</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Others (reference)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Occupational status</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Employed</td><td valign="top" align="left" rowspan="1" colspan="1">0.00 (0.01)</td><td valign="top" align="left" rowspan="1" colspan="1">0.99</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.75 (3.3)</td><td valign="top" align="left" rowspan="1" colspan="1">0.60</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Housewife</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.01 (0.02)</td><td valign="top" align="left" rowspan="1" colspan="1">0.51</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;3.39 (3.5)</td><td valign="top" align="left" rowspan="1" colspan="1">0.34</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Jobless</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.02 (0.03)</td><td valign="top" align="left" rowspan="1" colspan="1">0.48</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;3.33 (5.1)</td><td valign="top" align="left" rowspan="1" colspan="1">0.51</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Retired (reference)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Age (years)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.00 (0.00)</td><td valign="top" align="left" rowspan="1" colspan="1">0.12</td><td valign="top" align="left" rowspan="1" colspan="1">0.09 (0.1)</td><td valign="top" align="left" rowspan="1" colspan="1">0.25</td></tr></tbody></table><table-wrap-foot><fn id="tfn11-iprp-5-011"><p><bold>Abbreviations:</bold> CORFIS, Community Based Multiple Risk Factors Intervention Strategy; EQ-5D, EuroQoL-five dimension, health-related quality of life questionnaire; EQ-VAS, EQ-5D visual analog scale; GEE, generalized estimating equation; SE, standard error.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t5-iprp-5-011" position="float"><label>Table 5</label><caption><p>EQ-5D scores in hypertensive, diabetic, and hyperlipidemic patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" valign="top" align="left" colspan="1">Disease</th><th colspan="2" valign="top" align="left" rowspan="1">Hypertension
<hr/></th><th colspan="2" valign="top" align="left" rowspan="1">Diabetes
<hr/></th><th colspan="2" valign="top" align="left" rowspan="1">Hyperlipidemia
<hr/></th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">Intervention group</th><th valign="top" align="left" rowspan="1" colspan="1">Usual care group</th><th valign="top" align="left" rowspan="1" colspan="1">Intervention group</th><th valign="top" align="left" rowspan="1" colspan="1">Usual care group</th><th valign="top" align="left" rowspan="1" colspan="1">Intervention group</th><th valign="top" align="left" rowspan="1" colspan="1">Usual care group</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">EQ-5D index score</td><td valign="top" align="left" rowspan="1" colspan="1">n=306</td><td valign="top" align="left" rowspan="1" colspan="1">n=173</td><td valign="top" align="left" rowspan="1" colspan="1">n=268</td><td valign="top" align="left" rowspan="1" colspan="1">n=104</td><td valign="top" align="left" rowspan="1" colspan="1">n=292</td><td valign="top" align="left" rowspan="1" colspan="1">n=130</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Baseline</td><td valign="top" align="left" rowspan="1" colspan="1">0.93 (0.10)</td><td valign="top" align="left" rowspan="1" colspan="1">0.94 (0.09)</td><td valign="top" align="left" rowspan="1" colspan="1">0.92 (0.10)</td><td valign="top" align="left" rowspan="1" colspan="1">0.94 (0.09)</td><td valign="top" align="left" rowspan="1" colspan="1">0.93 (0.10)</td><td valign="top" align="left" rowspan="1" colspan="1">0.95 (0.09)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;End of study</td><td valign="top" align="left" rowspan="1" colspan="1">0.95 (0.09)</td><td valign="top" align="left" rowspan="1" colspan="1">0.95 (0.09)</td><td valign="top" align="left" rowspan="1" colspan="1">0.95 (0.10)</td><td valign="top" align="left" rowspan="1" colspan="1">0.94 (0.09)</td><td valign="top" align="left" rowspan="1" colspan="1">0.96 (0.09)</td><td valign="top" align="left" rowspan="1" colspan="1">0.95 (0.09)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;<italic>P</italic>-value<xref ref-type="table-fn" rid="tfn12-iprp-5-011">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td valign="top" align="left" rowspan="1" colspan="1">0.082</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td valign="top" align="left" rowspan="1" colspan="1">0.608</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td valign="top" align="left" rowspan="1" colspan="1">0.513</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">EQ VAS score</td><td valign="top" align="left" rowspan="1" colspan="1">n=302</td><td valign="top" align="left" rowspan="1" colspan="1">n=131</td><td valign="top" align="left" rowspan="1" colspan="1">n=262</td><td valign="top" align="left" rowspan="1" colspan="1">n=81</td><td valign="top" align="left" rowspan="1" colspan="1">n=288</td><td valign="top" align="left" rowspan="1" colspan="1">n=96</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Baseline</td><td valign="top" align="left" rowspan="1" colspan="1">71.9 (16.5)</td><td valign="top" align="left" rowspan="1" colspan="1">70.3 (25.8)</td><td valign="top" align="left" rowspan="1" colspan="1">69.5 (17.2)</td><td valign="top" align="left" rowspan="1" colspan="1">66.7 (27.2)</td><td valign="top" align="left" rowspan="1" colspan="1">70.0 (16.5)</td><td valign="top" align="left" rowspan="1" colspan="1">72.3 (25.8)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;End of study</td><td valign="top" align="left" rowspan="1" colspan="1">77.6 (14.8)</td><td valign="top" align="left" rowspan="1" colspan="1">72.2 (25.8)</td><td valign="top" align="left" rowspan="1" colspan="1">75.8 (15.9)</td><td valign="top" align="left" rowspan="1" colspan="1">69.5 (26.6)</td><td valign="top" align="left" rowspan="1" colspan="1">76.6 (15.1)</td><td valign="top" align="left" rowspan="1" colspan="1">75.1 (22.7)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;<italic>P</italic>-value<xref ref-type="table-fn" rid="tfn12-iprp-5-011">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td valign="top" align="left" rowspan="1" colspan="1">0.508</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td valign="top" align="left" rowspan="1" colspan="1">0.488</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td valign="top" align="left" rowspan="1" colspan="1">0.392</td></tr></tbody></table><table-wrap-foot><fn><p><bold>Notes:</bold></p></fn><fn id="tfn12-iprp-5-011"><label>*</label><p><italic>P</italic>-value based on paired <italic>t</italic>-test for within-group differences. EQ-5D scores were computed using the Malaysian index. Higher EQ-5D and EQ-VAS scores represent better quality of life.</p></fn><fn id="tfn13-iprp-5-011"><p><bold>Abbreviations:</bold> EQ-5D, EuroQoL-five dimension, health-related quality of life questionnaire; EQ VAS, EQ-5D visual analog scale.</p></fn></table-wrap-foot></table-wrap></floats-group></article>